Dynavax Technologies (DVAX -1.16%), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4 million, sharply ahead of analyst expectations of$86.7 million, and GAAP diluted earnings per share (EPS) of $0.14 versus a$0.10 consensus estimate. This result marks significant year-over-year growth, with both GAAP revenue and earnings well above the same period in 2024. The quarter stood out for record sales of H ...